secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-089329
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma Q2 net loss widens to $2.7M, cash $33.3M; merger with Oruka ongoing
--------------------------------------------------------------------------------

- Net loss $2.7M ($0.18/sh) vs $1.5M ($0.10) in Q2 2023, driven by $1.3M increase in G&A expenses.
- Cash $33.3M as of June 30, 2024, down from $37.4M at Dec 31, 2023; expects to fund ops through end of 2025.
- G&A expenses rose to $3.0M from $1.7M due to $0.9M merger-related professional fees and $0.4M CEO termination benefits (Dr. Bristow resigned April 3, 2024).
- Merger with Oruka Therapeutics remains pending; if not completed, company may pursue dissolution/liquidation.
- R&D expenses fell to $0.1M from $0.3M due to reduced headcount and end of grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017024089329/0000950170-24-089329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017024089329/abio-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer